Follows people treated with radiofrequency ablation for thyroid nodules
Tracks long-term results and quality of life in adults treated for thyroid nodules.
Plain-language title generated from the registry record
Registry title: Radiofrequency Ablation for Management of Benign/Indeterminate Thyroid Nodules and Low Risk Papillary Thyroid Cancers
Key facts
- Where
- Houston, United StatesSee the site
Where in United States
- MD Anderson Cancer CenterHouston, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- M.D. Anderson Cancer Center
- Trial code
- NCT07140757
- Record updated
- 16 September 2026
- Original description
To track the outcomes of patients who have been treated with RFA and its long-term effectiveness, and to learn more about the quality of life of patients who have received RFA in this study.Read full original descriptionShow less
Radiofrequency Ablation for Management of Benign/Indeterminate Thyroid Nodules and Low Risk Papillary Thyroid Cancers
To track the outcomes of patients who have been treated with RFA and its long-term effectiveness, and to learn more about the quality of life of patients who have received RFA in this study.
Exclusion: Participants meeting any of the following criteria will be excluded:; Participants considered unsuitable for RFA by the treating physician.
Eligibility Criteria; Participants scheduled to undergo ultrasound-guided RFA for the following conditions: benign thyroid nodules, indeterminate thyroid nodules, low-risk DTC, and recurrent PTC; Participant is over 18 years and is either not a surgical candidate or has declined surgery; Capable and willing to provide written informed consent; Participant has one of the following diagnoses:; Biopsy-proven benign thyroid nodules causing compressive and/or cosmetic symptoms who are requesting treatment,; Biopsy-proven indeterminate nodules (AUS or follicular neoplasm); Papillary thyroid carcinoma (PTC) without metastasis; Locally recurrent thyroid cancer (< 2 cm).